Niels van de Donk
Niels van de Donk
Associate Professor of Hematology, VU University Medical Center
Verified email at
Cited by
Cited by
Targeting CD38 with daratumumab monotherapy in multiple myeloma
HM Lokhorst, T Plesner, JP Laubach, H Nahi, P Gimsing, M Hansson, ...
New England Journal of Medicine 373 (13), 1207-1219, 2015
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
P Sonneveld, H Avet-Loiseau, S Lonial, S Usmani, D Siegel, ...
Blood, The Journal of the American Society of Hematology 127 (24), 2955-2962, 2016
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
J Krejcik, T Casneuf, IS Nijhof, B Verbist, J Bald, T Plesner, K Syed, K Liu, ...
Blood, The Journal of the American Society of Hematology 128 (3), 384-394, 2016
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA …
P Moreau, M Attal, C Hulin, B Arnulf, K Belhadj, L Benboubker, MC Béné, ...
The Lancet 394 (10192), 29-38, 2019
Teclistamab in relapsed or refractory multiple myeloma
P Moreau, AL Garfall, NWCJ van de Donk, H Nahi, JF San-Miguel, A Oriol, ...
New England Journal of Medicine 387 (6), 495-505, 2022
International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment
MA Dimopoulos, P Sonneveld, N Leung, G Merlini, H Ludwig, E Kastritis, ...
Journal of Clinical Oncology 34 (13), 1544-1557, 2016
CD38 antibodies in multiple myeloma: back to the future
NWCJ Van de Donk, PG Richardson, F Malavasi
Blood, The Journal of the American Society of Hematology 131 (1), 13-29, 2018
European Myeloma Network guidelines for the management of multiple myeloma-related complications
E Terpos, M Kleber, M Engelhardt, S Zweegman, F Gay, E Kastritis, ...
haematologica 100 (10), 1254, 2015
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
J Hillengass, S Usmani, SV Rajkumar, BGM Durie, MV Mateos, S Lonial, ...
The lancet oncology 20 (6), e302-e312, 2019
Monoclonal antibodies targeting CD 38 in hematological malignancies and beyond
NWCJ Van De Donk, ML Janmaat, T Mutis, JJ Lammerts van Bueren, ...
Immunological reviews 270 (1), 95-112, 2016
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma
IS Nijhof, T Casneuf, J Van Velzen, B van Kessel, AE Axel, K Syed, ...
Blood, The Journal of the American Society of Hematology 128 (7), 959-970, 2016
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study
SK Kumar, MA Dimopoulos, E Kastritis, E Terpos, H Nahi, H Goldschmidt, ...
Leukemia 31 (11), 2443-2448, 2017
CD38 antibodies in multiple myeloma: mechanisms of action and modes of resistance
NWCJ Van de Donk, SZ Usmani
Frontiers in immunology 9, 2134, 2018
Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab
IS Nijhof, RWJ Groen, HM Lokhorst, B Van Kessel, AC Bloem, ...
Leukemia 29 (10), 2039-2049, 2015
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma
M Engelhardt, E Terpos, M Kleber, F Gay, R Wäsch, G Morgan, M Cavo, ...
haematologica 99 (2), 232, 2014
A rational strategy for reducing on-target off-tumor effects of CD38-chimeric antigen receptors by affinity optimization
E Drent, M Themeli, R Poels, R de Jong-Korlaar, H Yuan, J de Bruijn, ...
Molecular therapy 25 (8), 1946-1958, 2017
Talquetamab, a T-cell–redirecting GPRC5D bispecific antibody for multiple myeloma
A Chari, MC Minnema, JG Berdeja, A Oriol, NWCJ van de Donk, ...
New England Journal of Medicine 387 (24), 2232-2244, 2022
Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma
NWCJ van de Donk, P Moreau, T Plesner, A Palumbo, F Gay, JP Laubach, ...
Blood, The Journal of the American Society of Hematology 127 (6), 681-695, 2016
The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma
HM Lokhorst, K Wu, LF Verdonck, LL Laterveer, NWCJ van de Donk, ...
blood 103 (11), 4362-4364, 2004
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
P Moreau, SK Kumar, J San Miguel, F Davies, E Zamagni, N Bahlis, ...
The Lancet Oncology 22 (3), e105-e118, 2021
The system can't perform the operation now. Try again later.
Articles 1–20